Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly: An observational study in Liguria Region, Italy

BACKGROUND: In September 2011 the European Medical Agency authorized the use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years. The same occurred in the US in December 2011 when the Food and Drug Administration approved the use of PCV13 in the same target age-group with in...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Hum Vaccin Immunother
मुख्य लेखकों: Durando, Paolo, Rosselli, Roberto, Cremonesi, Ilaria, Orsi, Andrea, Albanese, Erika, Barberis, Ilaria, Paganino, Chiara, Trucchi, Cecilia, Martini, Mariano, Marensi, Lorenzo, Turello, Valter, Study Group, the Ligurian Pneumococcal, Bregante, Alessandro, Cacciani, Roberto, Iudici, Rocco, La Marca, Diego, Pedano, Leonardo, Petrucci, Amadio Franco, Santolini, Maria, Sbisà, Valentina, Zacconi, Monica
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Taylor & Francis 2014
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514209/
https://ncbi.nlm.nih.gov/pubmed/25483531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.34420
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन